Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3

[1]  V. Lewis,et al.  Current and future therapeutic approaches for osteosarcoma , 2018, Expert review of anticancer therapy.

[2]  T. Zhu,et al.  Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese , 2017, Scientific Reports.

[3]  Masaki Kobayashi,et al.  Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug–drug interactions mediated by organic anion transporter 3 , 2017, Biopharmaceutics & drug disposition.

[4]  T. Buclin,et al.  Renal Drug Transporters and Drug Interactions , 2017, Clinical Pharmacokinetics.

[5]  Huijun Sun,et al.  P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. , 2016, Toxicology and applied pharmacology.

[6]  C. Pui,et al.  Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.

[7]  M. Iwaki,et al.  Stereoselective Inhibition of Methotrexate Excretion by Glucuronides of Nonsteroidal Anti-inflammatory Drugs via Multidrug Resistance Proteins 2 and 4 , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[8]  K. Horibe,et al.  Statistical analysis of relation between plasma methotrexate concentration and toxicity in high‐dose methotrexate therapy of childhood nonHodgkin lymphoma , 2015, Pediatric blood & cancer.

[9]  N. Fournier,et al.  Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3 , 2014, Drug Metabolism and Disposition.

[10]  F. Forouhar,et al.  A review of methotrexate‐associated hepatotoxicity , 2014, Journal of digestive diseases.

[11]  N. Bartlett,et al.  High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis , 2014, Leukemia & lymphoma.

[12]  L. Matherly,et al.  Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. , 2014, Current topics in membranes.

[13]  H. Wortelboer,et al.  Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. , 2013, Translational research : the journal of laboratory and clinical medicine.

[14]  Huijun Sun,et al.  MDR1 and OAT1/OAT3 Mediate the Drug-Drug Interaction between Puerarin and Methotrexate , 2013, Pharmaceutical Research.

[15]  A. Lescoute,et al.  Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. , 2010, Anticancer research.

[16]  A. Fujimura,et al.  Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. , 2010, European journal of pharmacology.

[17]  Y. Sawada,et al.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. , 2009, British journal of clinical pharmacology.

[18]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  A. Craft,et al.  High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma , 2004, Cancer.

[20]  R. Bremnes,et al.  Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes , 2004, Cancer Chemotherapy and Pharmacology.

[21]  J. Seymour,et al.  Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  R. Bremnes,et al.  The effect of vindesine on methotrexate hydroxylation in the rat. , 1991, Biochemical pharmacology.

[23]  J. Barbet,et al.  Methotrexate-vindesine association in leukemia: Pharmacokinetic study , 1985, Medical oncology and tumor pharmacotherapy.

[24]  R. Bender,et al.  The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells. , 1977, Cancer research.

[25]  V. Oliverio,et al.  Alteration of methotrexate uptake in human leukemia cells by other agents. , 1975, Cancer research.

[26]  I. Goldman,et al.  Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells. , 1973, The Journal of biological chemistry.